Article citationsMore>>

Dekkers, C.C.J., Petrykiv, S., Laverman, G.D., Cherney, D.Z., Gansevoort, R.T. and Heerspink, H.J.L. (2018) Effects of the SGLT-2 Inhibitor Dapagliflozin on Glomerular and Tubular Injury Markers. Diabetes, Obesity and Metabolism, 20, 1988-1993.
https://doi.org/10.1111/dom.13301

has been cited by the following article:

• TITLE: SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM

  AUTHORS: Rushi Patel, Terry Oroszi

  KEYWORDS: SGLT-2 Inhibitors, Type 2 Diabetes Mellitus, Cardiovascular Outcomes, Renal Protection, Glycemic Control

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.15 No.12, December 30, 2024

  ABSTRACT: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, safety, and potential benefits of SGLT-2 inhibitors in improving cardiovascular and renal outcomes in DM2 patients. A comprehensive review of clinical trials and studies on SGLT-2 inhibitors was conducted. SGLT-2 inhibitors significantly improve glycemic control, reduce cardiovascular mortality, and lower the risk of renal events in DM2 patients. SGLT-2 inhibitors offer substantial cardio-renal protection in DM2 management, though further research is needed to optimize their use.